Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13309270 | 0.80 | EPHX1 (0.39) | EPHX1TET2RECQLALDH1A1HSD17B10 | |
| SCHEMBL12128670 | 0.78 | KDM4E (0.36) | RIPK1ALDH1A1TSHR | |
| SCHEMBL19334206 | 0.78 | EPHX1 (0.53) | EPHX1TSHR | |
| SCHEMBL24492714 | 0.75 | RIPK1 (0.37) | RIPK1 | |
| SCHEMBL16091819 | 0.73 | CA1 (0.33) | RIPK1RECQL | |
| SCHEMBL9632175 | 0.72 | TET2 (0.58) | EPHX1TET2RECQLALDH1A1HSD17B10 | |
| SCHEMBL20987889 | 0.72 | ALDH1A1 (0.45) | RIPK1ALDH1A1TSHR | |
| SCHEMBL8009840 | 0.71 | RIPK1 (0.38) | EPHX1RIPK1ALDH1A1FKBP1ATSHR | |
| SCHEMBL12467629 | 0.71 | DPP4 (0.34) | RIPK1 | |
| SCHEMBL1230604 | 0.71 | MGAM (0.44) | RIPK1TET2RECQLALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR3A | EPHX1 1401/4885RIPK1 2293/4885TET2 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.